Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24

作者：

Vogel, AM

Lennon, DR

Broadbent, R

Byrnes, CA

Grimwood, K

Mildenhall, L

Richardson, V

Rowley, S

机构：

[1] Univ Auckland, Wellington, New Zealand

[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand

[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand

[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand

来源：

JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期

关键词：

consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;

D O I：

10.1046/j.1440-1754.2002.00057.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.

引用

页码：550 / 554

页数：5

共 50 条

[31] Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Chirico, Gaetano
Ravasio, Roberto
Sbarigia, Urbano
ITALIAN JOURNAL OF PEDIATRICS, 2009, 35
[32] Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants
Pedraz, C
Carbonell-Estrany, X
Figueras-Aloy, J
Quero, J
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : 823 - 827
[33] COST-EFFECTIVENESS OF PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) WITH PALIVIZUMAB IN PRETERM INFANTS IN COLOMBIA
Rosselli, D.
Rueda, J. D.
Ruiz, J. G.
VALUE IN HEALTH, 2013, 16 (03) : A75 - A75
[34] Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Lanari, Marcello
Silvestri, Michela
Rossi, Giovanni A.
CURRENT DRUG METABOLISM, 2013, 14 (02) : 216 - 225
[35] Current and emerging pharmacological treatments for respiratory syncytial virus infection in high-risk infants
Soto, Jorge A.
Loaiza, Ricardo A.
Echeverria, Sebastian
Ramirez, Robinson A.
Kalergis, Alexis M.
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1143 - 1158
[36] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
Robinson, Karen A.
Odelola, Olaide A.
Saldanha, Ian J.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
[37] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
Robinson, Karen A.
Odelola, Olaide A.
Saldanha, Ian J.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (05):
[38] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
Robinson, Karen A.
Odelola, Olaide A.
Saldanha, Ian
Mckoy, Naomi
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (02):
[39] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
Robinson, Karen A.
Odelola, Olaide A.
Saldanha, Ian J.
Mckoy, Naomi A.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
[40] Prevention of respiratory syncytial virus infections in high-risk infantsby monoclonal antibody (palivizumab)
Groothuis, JR
Nishida, H
PEDIATRICS INTERNATIONAL, 2002, 44 (03) : 235 - 241

← 1 2 3 4 5 →